But the company has just presented early stage data showing the formulation to be as effective as injectable insulin – and says a future advance in drug delivery could still make it a reality.

NovoPen ®, the first insulin pen injector, was introduced in 1985. This article reviews the published evidence over two decades of use of the NovoPen ® family of injection devices in diabetes ...

Its effect lasts for about two to three hours, closely resembling the body’s own response to insulin. This is the first and only non-injectable insulin to be developed for patients of both type ...

Insulin therapy, vital for diabetes management, is often misunderstood. It's not a sign of failure or addiction, nor does it ...

After years of controversy, stem cells are on the cusp of cures for conditions like epilepsy and type 1 diabetes.

The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), ...

Medicare Part D plans cover injectable insulin not associated with the use of durable insulin pumps, which are covered under Part B. Considering nearly 30% of adults ages 65 and older have ...

Developed in collaboration with consultant pharmacists and nursing professionals, the video addresses critical steps when clinically administering insulin via injection pens and is particularly ...

(RTTNews) - Eli Lilly and Company said the Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly (LLY). The ...

“Afrezza is a rapid-acting insulin delivered through an inhaler as compared to current insulins which are given as injections. Taken at the beginning of a meal, Afrezza dissolves rapidly upon ...

Lilly and EVA Pharma receive Egyptian Drug Authority approval for insulin glargine injection and release of locally manufactured insulin in Egypt: Indianapolis Thursday, December ...